Charitable sports promotion: sponsorship receipts alone did not defeat registration where funds supported tournaments and player development activitie...
Overdue associated-enterprise receivables: debt-free status defeated notional-interest adjustment, while employee stock-option costs qualified as busi...
Retrospective assessment-limitation amendments validate final orders while contemporaneous segment data governs transfer-pricing comparability and tol...
Transfer pricing adjustments must track international transactions, while unsupported AMP adjustments and unsuitable manufacturing comparables require...
Transfer-pricing adjustments must reflect functional comparability, working-capital effects, and avoid duplicating interest on associated-enterprise r...
Bulk drugs and active pharmaceutical ingredients (APIs) may qualify as "All Drugs and medicines" for concessional IGST treatment where their character, intended use and statutory compliance bring them within the inclusive definition of "drug" under the Drugs and Cosmetics Act. Classification under Customs Tariff Chapters 28 or 29 does not preclude coverage by the description-based drugs and medicines entry, which prevails over general entries for inorganic and organic chemicals. Imports for testing, clinical research, bioavailability or bioequivalence studies retain their pharmaceutical character. The concessional rate applies only if the particular bulk drug or API is not within the specified nil-rate exclusion.
Bulk drugs and active pharmaceutical ingredients (APIs) may qualify as "All Drugs and medicines" for concessional IGST treatment where their character, intended use and statutory compliance bring them within the inclusive definition of "drug" under the Drugs and Cosmetics Act. Classification under Customs Tariff Chapters 28 or 29 does not preclude coverage by the description-based drugs and medicines entry, which prevails over general entries for inorganic and organic chemicals. Imports for testing, clinical research, bioavailability or bioequivalence studies retain their pharmaceutical character. The concessional rate applies only if the particular bulk drug or API is not within the specified nil-rate exclusion.
Note: It is a system-generated summary and is for quick reference only.